Skip to main content
. 2018 Nov 8;294(1):314–326. doi: 10.1074/jbc.RA118.004126

Table 2.

Summary of Vmax, Km, kcat, and Ki

Vmax Km kcat Ki n
μm s1 μm 104 s1 nm
acSPD
    No antibody 391 ± 38 387 ± 74 39 ± 4 NAa 5
    aZ-mAb-1 184 ± 38b 197 ± 64b 18 ± 4 NA 3
    aZ-mAb-2 348 ± 22 489 ± 45 35 ± 2 NA 3
    aZ-mAb-3 152 ± 27b 166 ± 36b 15 ± 3 NA 3
    aZ-mAb-4 349 ± 61 347 ± 87 35 ± 6 NA 4
    aZ-mAb-5 339 ± 60 421 ± 102 34 ± 6 NA 3
    aZ-mAb-6 371 ± 35 857 ± 84b 37 ± 4 21 ± 2 3
    aZ-mAb-7 365 ± 19 1172 ± 255b 37 ± 2 9 ± 2 3
    aZ-mAb-9 281 ± 58b 424 ± 109 28 ± 6 NA 3
    aZ-mAb-10 308 ± 42b 451 ± 102 31 ± 4 NA 3

zSPD
    No antibody 295 ± 93 256 ± 54 0.77 ± 0.09 NA 10
    aZ-mAb-4 445 ± 14b 193 ± 9 0.89 ± 0.03 NA 3
    aZ-mAB-6 260 ± 14 901 ± 39b 0.52 ± 0.03 NA 3
    aZ-mAb-7 346 ± 8 609 ± 14b 0.69 ± 0.02 NA 3

a NA, not applicable.

b Statistically significant difference from “no antibody” by unpaired t test calculated using GraphPad QuickCalcs online software.